

## Case Study



# Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT-1) - an lncRNA driving cancer progression

## The Purpose

To identify and explore the role of MALAT-1 in disease pathogenesis in different oncological indications using GOBIOM Biomarker Platform.

## About the Client

**COMPANY**  
Big Pharma

**LOCATION**  
US

**THERAPEUTIC AREA**  
Oncology

## Client Requirement

The client is a large pharma based out of US and focused primarily on research and development of therapeutics targeting various cancers. They are exploring the potential of MALAT-1 as a therapeutic target in multiple tumors. In this case study we explore the role of MALAT-1 in numerous cancers.

## Methodology

GOBIOM database was queried to identify utilities of MALAT-1 in different oncological indications.

## Results

### Utility of MALAT-1 and its associations with disease indicators in different oncological indications

Lymph node metastasis

Local invasion

Tumor stage

Tumor size

Tumor grade

Cell cycle progression

Tumor volume


Apoptosis

Cell invasion

Cell proliferation

Cell motility/migration

Blood brain permeability



Recurrence free survival

Progression free survival


Recurrence/relapse

Disease free survival

Overall survival

## Biomarker Landscape

### MALAT-1 biomarker in different oncological indications (sorted by number of clinical studies)








## Excelra's Contribution

MALAT-1 has been most researched in Breast cancer, Non-small cell lung cancer, Gastric cancer, Osteosarcoma, and Ovarian cancer. The results conclude that MALAT-1 indeed plays an important role in disease progression through its involvement in tumorigenesis.

GOBIOM addressed critical questions in disease process, clinical research and in drug discovery and development.

## Excelra's Service Portfolio

	Insights	Data
 <b>Discovery</b>	<ul style="list-style-type: none"><li>• Data Science Driven Drug Discovery</li><li>• Target Identification</li><li>• Target Dossier Services</li></ul>	<ul style="list-style-type: none"><li>• Chemistry Curation Services</li><li>• GOSTAR Structure Activity Relationship database</li></ul>
 <b>Translational</b>	<ul style="list-style-type: none"><li>• Biomarker Discovery</li><li>• Drug Repositioning</li><li>• Life Cycle Management</li><li>• Systems Biology Informatics</li></ul>	<ul style="list-style-type: none"><li>• Biology Curation Services</li><li>• GOBIOM Biomarker intelligence database</li></ul>
 <b>Clinical</b>	<ul style="list-style-type: none"><li>• Precision Oncology Informatics</li><li>• Clinical Pharmacology</li></ul>	<ul style="list-style-type: none"><li>• Clinical Trial Outcomes Database</li></ul>
 <b>Value Evidence</b>	<ul style="list-style-type: none"><li>• Outcomes Research</li><li>• Epidemiology Modelling</li><li>• Economic Modelling</li><li>• Value Evidence Communication</li></ul>	<ul style="list-style-type: none"><li>• RWE &amp; Big Data Realization</li><li>• SLR &amp; Meta-analysis</li></ul>
 <b>Technology Solutions</b>	<ul style="list-style-type: none"><li>• Enterprise Data Strategy</li><li>• Enterprise Cloud Ops</li><li>• Enterprise Digital Transformation</li></ul>	

For more information, visit <https://www.excelra.com/translational/#gobiom>



### About Excelra

Excelra's data and analytics solutions empower innovation in life sciences across the value chain from discovery to market. The Excelra Edge comes from a seamless amalgamation of proprietary curated data assets, deep domain expertise and data science. The company's multifaceted teams harmonize and analyse large volumes of disparate unstructured data using cutting-edge technologies. We galvanize data-driven decisions to unlock operational efficiencies to accelerate drug discovery and development. Over the past 18 years, Excelra has been the preferred data and analytics partner to over 90 global clients, including 15 of the top 20 large Pharma.